Blueprint Medicines has patented a method for treating RET-altered non-small cell lung cancer by administering a selective RET inhibitor like Compound 1. The method involves oral administration of specific doses of the inhibitor once daily. GlobalData’s report on Blueprint Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Blueprint Medicines Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Blueprint Medicines, Cancer treatment biomarkers was a key innovation area identified from patents. Blueprint Medicines's grant share as of January 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of ret-altered non-small cell lung cancer

Source: United States Patent and Trademark Office (USPTO). Credit: Blueprint Medicines Corp

A recently granted patent (Publication Number: US11872192B2) outlines a method for treating patients with rearranged during transfection (RET)-altered non-small cell lung cancer (NSCLC) by orally administering varying doses of Compound 1 or its salt. The method involves daily doses of 200 mg, 300 mg, or 400 mg of Compound 1 to the patient, depending on the specific requirements of the treatment regimen.

The patent specifies that the treatment is particularly effective for NSCLC cases with a RET-gene rearrangement, including RET fusions involving genes such as CLIP1, PIBF1, BCR, and others. The method also covers scenarios where the patient has previously undergone treatment with platinum-based drugs like cisplatin or carboplatin, as well as cabozantinib or vandetanib. The administration of Compound 1 can be in the form of solid dosage forms like tablets or capsules, ensuring ease of use and compliance for patients undergoing this targeted therapy for metastatic RET-altered NSCLC.

To know more about GlobalData’s detailed insights on Blueprint Medicines, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies